Lv61
3106 积分 2023-12-13 加入
SOHO State of the Art Updates and Next Questions | Beyond Romidepsin: Novel Therapeutic Targets and Emerging Strategies for Relapsed and Refractory Peripheral T-Cell Lymphoma
27分钟前
待确认
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
34分钟前
待确认
Inhibitors of IAP/XIAP enhance activity of sacituzumab govitecan
1个月前
已完结
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
1个月前
已完结
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
1个月前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
1个月前
已完结
Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes
2个月前
已完结
A systematic literature review of MTAP deletions in solid and hematologic Cancers
2个月前
已完结
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration
2个月前
已完结
BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion ( MTAP -del): Clinical update and first report of pharmacokinetics (PK) and pharmacodynamic (PD) analyses from CA240-0007
2个月前
已完结
皖公网安备34019202002308
